Summary
Thirty-two patients affected by amyotrophic lateral sclerosis (ALS) were included in a controlled, open therapeutic trial with branched chain amino acids (BCAA). Patients with bulbar muscle involvement were evaluated separately. No statistically significant differences were found in the clinical outcome between the patients treated and the control groups. Blood l-glutamate levels measured in eight patients were normal. The failure of BCAA in the treatment of the patients could be due to different disorders with unpredictable outcome included under the diagnosis of ALS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bernt E, Bergmeyer HU (1974) l-Glutamate. UV-assay with glutamate dehydrogenase and NAD. In: Bergmeyer HU (ed) Methods of enzymatic analysis, 2nd edn. Verlag Chemie, Weinheim, pp 1704–1708
Meier DH, Schott K-J (1988) Free amino acid pattern of cerebrospinal fluid in amyotrophic lateral sclerosis. Acta Neurol Scand 77:50–53
Mulder DW, Kurland LT, Offord KP, Beard CM (1986) Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology 36:511–517
Norris FH Jr, Calanchini PR, Fallat RJ, Panchari S, Jewett B (1974) The administration of guanidine in amyotrophic lateral sclerosis. Neurology 24:721–728
Patten BM, Harati Y, Acosta L, Jung S-S, Felmus MT (1978). Free amino acid levels in amyotrophic lateral sclerosis. Ann Neurol 3:305–309
Patten BM, Kurlander HM, Evans B (1982) Free amino acid concentrations in spinal tissue from patients dying of motor neuron disease. Acta Neurol Scand 66:594–599
Perry TL, Hansen S, Jones K (1987) Brain glutamate in amyotrophic lateral sclerosis. Neurology 37:1845–1848
Plaitakis A, Caroscio JT (1987) Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 22:575–579
Plaitakis A, Constantakakis E, Smith J (1988) The neuroexitocitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann Neurol 24:446–449
Plaitakis A, Smith J, Mandelli J, Yahr MD (1988) Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis. Lancet I:1015–1018
Poser CM, Johnson M, Bunch LD (1965) Serum amino acid studies in amyotrophic lateral sclerosis. I. Results or arginine tolerance tests. Arch Neurol 12:604–609
Rose FC (1977) Clinical aspects of motor neuron disease. In: Rose FC (ed) Motor neuron disease. Pitman, London, pp 1–114
Ross SM, Seelig M, Spencer PS (1987) Specific antagonism of excitotoxic action of “uncommon” amino acids assayed in organotypic mouse cortical cultures. Brain Res 425:120–127
Rowland LP (1987) Motor neuron diseases and amyotrophic lateral sclerosis: research progress. Trends Neurosci 10:393–398
Spencer PS, Nunn PB, Hugon J, Ludolph A, Ross SM, Roy DN, Schaumburg HH, Soiefer A (1968) Primate motor neuron disorders induced by chemically related excitatory neurotoxins isolated from Guamanian cycad and Indian chickling pea. Muscle Nerve [Suppl] 9:108
Spencer PS, Roy DN, Ludolph A, Hugon J, Dwivedi MP, Schaumburg HH (1986) Lathyrism: evidence for role of the neuroexcitatory aminoacid BOAA. Lancet II:1066–1067
Steele JC, Guzman T (1987) Observations about amyotrophic lateral sclerosis and the parkinsonism-dementia complex of Guam with regard to epidemiology and etiology. Can J Neurol Sci 14:358–362
Tandan R, Bradley WG (1985) Amyotrophic lateral sclerosis. I. Clinical features, pathology, and ethical isuues in management. Ann Neurol 18:271–80
Yoshino Y, Koike H, Akai K (1979) Free amino acids in motor cortex of amyotrophic lateral sclerosis. Experientia 35:219–220
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Testa, D., Caraceni, T. & Fetoni, V. Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis. J Neurol 236, 445–447 (1989). https://doi.org/10.1007/BF00328503
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00328503